CRISPR Therapeutics (CRSP) Expected to Announce Quarterly Earnings on Monday

Key Points

• CRISPR Therapeutics is set to release its Q2 2025 earnings on August 4th, with analysts predicting a loss of ($1.54) per share and revenues of $6.44 million.
• The recent earnings report showed CRISPR Therapeutics had a loss of ($1.58) per share, missing expectations and reflecting a significant negative net margin of 1,023.64%.
• CRISPR stock has a market capitalization of $5.59 billion, with various analysts placing target prices ranging from $47.00 to $82.00 and an average rating of "Hold".

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of ($1.54) per share and revenue of $6.44 million for the quarter.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same period last year, the company earned ($1.43) EPS. The firm's revenue for the quarter was up 71.6% compared to the same quarter last year. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock traded down $0.43 during midday trading on Thursday, reaching $57.25. The company's stock had a trading volume of 1,955,355 shares, compared to its average volume of 2,566,992. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $71.13. The stock's 50 day simple moving average is $48.88 and its 200 day simple moving average is $43.12. The firm has a market capitalization of $4.94 billion, a PE ratio of -12.66 and a beta of 1.82.

Insiders Place Their Bets

In related news, Director Simeon George bought 989,812 shares of the stock in a transaction that occurred on Wednesday, July 16th. The stock was acquired at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the transaction, the director directly owned 1,730,179 shares in the company, valued at approximately $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the transaction, the insider directly owned 6,068 shares of the company's stock, valued at approximately $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CRSP. Woodline Partners LP increased its position in CRISPR Therapeutics by 34.3% in the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company's stock valued at $4,645,000 after buying an additional 34,883 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of CRISPR Therapeutics by 28.2% in the 1st quarter. Royal Bank of Canada now owns 142,696 shares of the company's stock worth $4,856,000 after buying an additional 31,392 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in CRISPR Therapeutics in the first quarter valued at approximately $861,000. 69.20% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on CRSP shares. Wall Street Zen upgraded CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. The Goldman Sachs Group dropped their price objective on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Chardan Capital restated a "buy" rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a report on Thursday, June 26th. JMP Securities restated a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $81.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, July 8th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $71.31.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.